(Q33317794)

25 July 2017

1 reference

title

Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies (English)

1 reference

25 July 2017

1 reference

3

Toni K Choueiri

1 reference

25 July 2017

Ali-Reza Golshayan

1

1 reference

25 July 2017

Ashley J Brick

series ordinal

2

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

25 July 2017

1 reference

25 July 2017

volume

4

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

85-92

1 reference

25 July 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Hypoxia-inducible factor-1 and oncogenic signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Response of intracranial metastases to erlotinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Metastatic renal carcinoma comprehensive prognostic system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Gene expression profiling of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.1.85

21 January 2018

Identifiers

DOI

10.2217/14796694.4.1.85

1 reference

25 July 2017

1 reference